Artikel Alle Rechte vorbehalten
referiert
Veröffentlicht

Characterizing Adversity of Lysosomal Accumulation in Nonclinical Toxicity Studies: Results from the 5th ESTP International Expert Workshop.

Zugehörigkeit
1 Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Lenz, B.;
Zugehörigkeit
1 Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Braendli-Baiocco, A.;
Zugehörigkeit
2 Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
Engelhardt, J.;
Zugehörigkeit
3 Charles River Laboratories, Lyon, France.
Fant, P.;
Zugehörigkeit
1 Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Fischer, H.;
Zugehörigkeit
4 Center for Food Safety and Applied Nutrition (CFSAN), U.S. Food and Drug Administration, College Park, Maryland, USA.
Francke, S.;
Zugehörigkeit
5 Axcelead Drug Discovery Partners, Inc., Kanagawa, Japan.
Fukuda, R.;
Zugehörigkeit
6 Department of Experimental Toxicology and Ecology, BASF SE, Ludwigshafen, Germany.
Gröters, S.;
Zugehörigkeit
7 Institute of Environmental Toxicology, Ibaraki, Japan.
Harada, T.;
Zugehörigkeit
8 Global Medical, Clinical and Regulatory Affairs, Global Preclinical Development and Management, Fresenius-Kabi Deutschland GmbH, Bad Homburg, Germany.
Harleman, H.;
Zugehörigkeit
9 Merck, Darmstadt, Germany.
Kaufmann, W.;
Zugehörigkeit
1 Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Kustermann, S.;
Zugehörigkeit
10 Nonclinical Drug Safety Germany, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Nolte, T.;
Zugehörigkeit
11 Global Pathology, DSRD, Pfizer WRD, Groton, Connecticut, USA.
Palazzi, X.;
Zugehörigkeit
10 Nonclinical Drug Safety Germany, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Pohlmeyer-Esch, G.;
Zugehörigkeit
12 Global Preclinical Safety, AbbVie, Ludwigshafen, Germany.
Popp, A.;
Zugehörigkeit
13 Covance Laboratories, Inc., Rueil-Malmaison, France.
Romeike, A.;
Zugehörigkeit
14 Department of Chemicals and Product Safety, German Federal Institute for Risk Assessment, Berlin, Germany.
Schulte, Agnes;
Zugehörigkeit
15 Department of Pharmacological Sciences, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Lima, B Silva;
Zugehörigkeit
11 Global Pathology, DSRD, Pfizer WRD, Groton, Connecticut, USA.
Tomlinson, L.;
Zugehörigkeit
16 CDER, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Willard, J.;
Zugehörigkeit
17 Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA.
Wood, C. E.;
Zugehörigkeit
18 Food Safety Commission, Cabinet Office, Tokyo, Japan.
Yoshida, M.

Lysosomes have a central role in cellular catabolism, trafficking, and processing of foreign particles. Accumulation of endogenous and exogenous materials in lysosomes represents a common finding in nonclinical toxicity studies. Histologically, these accumulations often lack distinctive features indicative of lysosomal or cellular dysfunction, making it difficult to consistently interpret and assign adverse dose levels. To help address this issue, the European Society of Toxicologic Pathology organized a workshop where representative types of lysosomal accumulation induced by pharmaceuticals and environmental chemicals were presented and discussed. The expert working group agreed that the diversity of lysosomal accumulations requires a case-by-case weight-of-evidence approach and outlined several factors to consider in the adversity assessment, including location and type of cell affected, lysosomal contents, severity of the accumulation, and related pathological effects as evidence of cellular or organ dysfunction. Lysosomal accumulations associated with cytotoxicity, inflammation, or fibrosis were generally considered to be adverse, while those found in isolation (without morphologic or functional consequences) were not. Workshop examples highlighted the importance of thoroughly characterizing the biological context of lysosomal effects, including mechanistic data and functional in vitro readouts if available. The information provided here should facilitate greater consistency and transparency in the interpretation of lysosomal effects.

Zitieren

Zitierform:
Zitierform konnte nicht geladen werden.

Zugriffsstatistik

Gesamt:
Volltextzugriffe:
Metadatenansicht:
12 Monate:
Volltextzugriffe:
Metadatenansicht:

Rechte

Nutzung und Vervielfältigung:
Alle Rechte vorbehalten